Targeted Therapies

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA.

View the full paper here

IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell functino against ovarian cancer.

Felices M, Chu S, Kodal B, Bendzick L, Ryan C, Lenvik AJ, Boylan KLM, Wong HC, Skubitz APN, Miller JS, Geller MA.

View the full paper here. 

Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

Uppendahl LD, Felices MD, Bendzick L, Ryan C, Kodal B, Hinderlie P, Boylan KLM, Skubitz APN, Miller JS, Geller MA.

View the paper here.